CN102439441B - 用于肾损伤和肾衰竭的诊断及预后方法和组合物 - Google Patents

用于肾损伤和肾衰竭的诊断及预后方法和组合物 Download PDF

Info

Publication number
CN102439441B
CN102439441B CN201080014932.1A CN201080014932A CN102439441B CN 102439441 B CN102439441 B CN 102439441B CN 201080014932 A CN201080014932 A CN 201080014932A CN 102439441 B CN102439441 B CN 102439441B
Authority
CN
China
Prior art keywords
subject
renal
threshold
concentration
likelihood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080014932.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102439441A (zh
Inventor
J·安德贝里
J·格雷
P·麦克弗森
K·中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astute Medical Inc
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of CN102439441A publication Critical patent/CN102439441A/zh
Application granted granted Critical
Publication of CN102439441B publication Critical patent/CN102439441B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201080014932.1A 2009-02-06 2010-02-05 用于肾损伤和肾衰竭的诊断及预后方法和组合物 Expired - Fee Related CN102439441B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15039509P 2009-02-06 2009-02-06
US16241509P 2009-03-23 2009-03-23
PCT/US2010/023297 WO2010091236A1 (en) 2009-02-06 2010-02-05 Methods and compositions for diagnosis and prognosis of renal injury and failure

Publications (2)

Publication Number Publication Date
CN102439441A CN102439441A (zh) 2012-05-02
CN102439441B true CN102439441B (zh) 2016-03-09

Family

ID=42542390

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080014932.1A Expired - Fee Related CN102439441B (zh) 2009-02-06 2010-02-05 用于肾损伤和肾衰竭的诊断及预后方法和组合物

Country Status (8)

Country Link
US (1) US20120053072A1 (https=)
EP (1) EP2394166B1 (https=)
JP (1) JP2012517594A (https=)
CN (1) CN102439441B (https=)
AU (1) AU2010210540B2 (https=)
CA (1) CA2751435A1 (https=)
NZ (2) NZ601575A (https=)
WO (1) WO2010091236A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501456A (ja) 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
EP2324354B1 (en) 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
ES2836218T3 (es) 2008-10-21 2021-06-24 Astute Medical Inc Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
EP2913676A1 (en) 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010279249B2 (en) 2009-02-06 2015-08-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010315008B2 (en) 2009-11-07 2015-12-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011213684B2 (en) 2010-02-05 2014-11-20 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ701807A (en) 2010-02-26 2015-05-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IN2012MN02812A (https=) 2010-06-23 2015-05-22 Astute Medical Inc
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130316370A1 (en) * 2010-10-07 2013-11-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012094658A2 (en) * 2011-01-08 2012-07-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012103450A2 (en) 2011-01-29 2012-08-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
TW201250248A (en) * 2011-04-25 2012-12-16 Kyowa Medex Co Ltd Prognostication method of renal failure
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
WO2013130591A1 (en) * 2012-02-27 2013-09-06 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2018518676A (ja) * 2015-06-11 2018-07-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN109073620A (zh) * 2016-02-22 2018-12-21 健康跨度Dx公司 用于预防或降低急性肾损伤的方法
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
US10592554B1 (en) * 2017-04-03 2020-03-17 Massachusetts Mutual Life Insurance Company Systems, devices, and methods for parallelized data structure processing

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1429031A1 (ru) * 1986-06-20 1988-10-07 Калининский Государственный Медицинский Институт Способ дифференциальной диагностики гломерулонефрита и пиелонефрита
EP0828159A1 (en) * 1996-09-03 1998-03-11 Bayer Corporation Method for the detection of lysozyme
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
US20050112688A1 (en) * 2002-12-06 2005-05-26 Huaizhong Hu Systems and methods for characterizing kidney diseases
WO2008116867A1 (en) * 2007-03-26 2008-10-02 Novartis Ag Predictive renal safety biomarkers and biomarker signatures to monitor kidney function

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
RU2180965C1 (ru) 2000-07-03 2002-03-27 Габбасова Наталья Вадимовна Способ дифференциальной диагностики заболеваний почек
AUPR005600A0 (en) * 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
FI20010673A7 (fi) * 2001-03-30 2002-10-01 Metso Minerals Tampere Oy Järjestelmä tiedon keräämiseksi
US7138230B2 (en) * 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
WO2008060607A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
JP5661457B2 (ja) * 2007-06-06 2015-01-28 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． 腎疾患の予測診断

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1429031A1 (ru) * 1986-06-20 1988-10-07 Калининский Государственный Медицинский Институт Способ дифференциальной диагностики гломерулонефрита и пиелонефрита
EP0828159A1 (en) * 1996-09-03 1998-03-11 Bayer Corporation Method for the detection of lysozyme
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
US20050112688A1 (en) * 2002-12-06 2005-05-26 Huaizhong Hu Systems and methods for characterizing kidney diseases
WO2008116867A1 (en) * 2007-03-26 2008-10-02 Novartis Ag Predictive renal safety biomarkers and biomarker signatures to monitor kidney function

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biomarkers of Acute Kidney Injury;Vishal S.Vaidya et al;《ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY》;20090911;463-493 *
Diagnostic significance of urinary enzymes in detecting acute rejection crises in renal transplant recipients depending on expression of results illustrated through the example of alanine aminopeptidase;Klaus Jung et al;《Clinical Biochemistry》;19850831;第18卷;摘要，附图1,3，第101页 *
Urinary clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries;Sumi Hidaka et al;《regular article》;20021002;289-296 *
Urinary high density lipoprotein in minimal change glomerular disease and chronic glomerulopathies;Maria Lopes-Virella et al;《Clinica Chimica Acta》;19791231;第94卷;73-81页，摘要，列表1 *

Also Published As

Publication number Publication date
EP2394166A1 (en) 2011-12-14
EP2394166B1 (en) 2016-07-13
CA2751435A1 (en) 2010-08-12
HK1167455A1 (zh) 2012-11-30
JP2012517594A (ja) 2012-08-02
CN102439441A (zh) 2012-05-02
EP2394166A4 (en) 2012-09-26
AU2010210540A1 (en) 2011-09-15
WO2010091236A1 (en) 2010-08-12
AU2010210540B2 (en) 2015-06-18
US20120053072A1 (en) 2012-03-01
NZ594771A (en) 2013-06-28
NZ601575A (en) 2014-08-29
WO2010091236A9 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
CN102439441B (zh) 用于肾损伤和肾衰竭的诊断及预后方法和组合物
CN105074466B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102791885B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102725636B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN103874923B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
JP7217796B2 (ja) 腎障害および腎不全の診断および予後のための方法および組成物
CN102792161B (zh) 肾损伤和肾衰竭的诊断及预后的方法及组合物
CN102369293B (zh) 肾损伤和肾衰竭的诊断及预后
CN102711827B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102597258B (zh) 肾损伤和肾衰竭的诊断及预后
CN102576011B (zh) 用于肾损伤和肾衰竭的诊断及预后的组合物和方法
CN103080743B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN103238068B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN103858008B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102725635B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102884205B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102576012B (zh) 用于肾损伤和肾衰竭的诊断及预后方法和组合物
CN107003325A (zh) 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN104379758A (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN104335045B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN104583774A (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN105209914B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN107709993A (zh) 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
CN107735147A (zh) 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
HK1167455B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1167455

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1167455

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160309

Termination date: 20170331